Home/Biosimilar Atlas/Interferon alfa-2b/Intas peginterferon alfa-2b

Intas peginterferon alfa-2b

Interferon alfa-2b biosimilar developed by Intas Pharmaceuticals. Reference product Intron A and PegIntron (Merck).

Brands by market: Brand not published by CDSCO (India) · Commercial partner or holder: Intas Pharmaceuticals · Company profile
FDANot listed
EMANot listed
MHRANot listed
PMDANot listed
HCNot listed
CDSCOApr 2013permitted
EDENot listed
Approved or registered in 1 of 7 markets
Connections
Interferon alfa-2bmoleculeIntas Pharmaceuticalsdeveloper1 of 7markets0trials behind it11other products, same developer2rival developers in its markets

About Intas peginterferon alfa-2b

Intas received its pegylated interferon alfa-2b permission in India in April 2013, for hepatitis C and B, the second Indian pegylated interferon.

Status by market

FDA

United States

Not listed by FDA.

EMA

European Union

Not listed by EMA.

MHRA

United Kingdom

Not listed by MHRA.

PMDA

Japan

Not listed by PMDA.

HC

Canada

Not listed by HC.

CDSCO

India

Central Drugs Standard Control OrganisationApproved
Brand
Not published by CDSCO (INN only)
Holder or applicant
Intas Biopharmaceuticals Ltd
Pathway
Similar Biologic, manufacture and marketing permission
Approved
Apr 2013
Application or permission
MF-89/2013
Indications as licensed
Chronic hepatitis C and B
Presentations
Pegylated interferon alfa-2b in vials and syringes
Source
S014 (CDSCO) · checked Sep 2026
EDE

United Arab Emirates

Not listed by EDE.

Other developers in the same markets

Where Intas peginterferon alfa-2b holds an approval, these are the other interferon alfa-2b biosimilars approved in that market.

MarketRivalsDevelopers (product)
CDSCO2Not stated in the CDSCO list (USV interferon alfa-2b), Zydus Lifesciences (Zydus peginterferon alfa-2b)

Same developer, other molecules

Other biosimilars in the Atlas developed by Intas Pharmaceuticals: Accofil / Filkri, Intas bevacizumab, Intas etanercept, Intas follitropin alfa, Intas pertuzumab, Intas rituximab, Intas trastuzumab, Osvyrti / Jubereq, Pelgraz / Ennumo, Rexatilux / Razumab, Sondelbay / Intas teriparatide.

Chronology

Sources

All interferon alfa-2b biosimilars

Planning interferon alfa-2b biosimilar development?

EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.

Talk to a biosimilar regulatory consultant
Data current to September 2026.